Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
Michael A. Morse(Duke Medical Center), Timothy M. Clay(Duke Medical Center), Carey K. Anders(Duke University), Donna Niedzwiecki(Duke University), Takuya Osada(Rakuten (Japan)), Gayathri R. Devi(Medical University of South Carolina), Amy Hobeika(Duke Medical Center), P. Kelly Marcom(Duke University), Kimberly Blackwell(Duke University), H. Kim Lyerly(Duke University)
Cited by 45
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k